The Development of Adjuvanted Recombinant Vaccines Against Infectious Diseases
A special issue of Vaccines (ISSN 2076-393X). This special issue belongs to the section "Vaccine Adjuvants".
Deadline for manuscript submissions: 31 March 2025 | Viewed by 189
Special Issue Editor
Interests: infectious diseases; recombinant vaccines; adjuvants; delivery systems
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
While significant progress has been made in preventing and controlling infectious diseases globally, humanity continues to suffer from their devastating effects. Vaccines play a crucial role in combating infectious diseases. Many successful vaccines have been developed to immunize against human infectious diseases, thereby reducing morbidity and mortality. Nevertheless, there remains a need for improved or novel vaccines to provide optimal and long-lasting protection against various infectious diseases. One strategy for developing new and more effective vaccines involves using immunogenic proteins in the form of recombinant vaccines. However, recombinant proteins are generally weak antigens and necessitate appropriate adjuvants and delivery systems to enhance their protective efficacy. Incorporating adjuvants can reduce the antigens required to elicit an optimal immune response, thereby minimizing adverse effects at the inoculation site.
This Special Issue invites original research and review articles on the efficacy of adjuvanted recombinant vaccines in preclinical and clinical trials against bacterial, parasitic, fungal, and viral infections for consideration.
Prof. Dr. Abu Salim Mustafa
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- infectious diseases
- vaccines
- recombinant antigens
- adjuvants
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.
